Carlos Cruchaga, PhD, director of the NeuroGenomics and Informatics Center at Washington University, discusses emerging blood-based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in Alzheimer disease.
Feature|Articles|July 21, 2026
The Hidden Cost of the Beautiful Game: Part 2
Fact checked by: Marco Meglio, Kelly King
From concussion recognition to blood-based biomarkers and the long-term effects of repetitive heading, neurologists discuss how emerging research is changing the understanding of brain injury in the world's most popular sport.
Advertisement
Advertisement
One effort to better understand that longer timeline is underway in London, England, where researchers with the Advanced Brain Health Clinic are studying retired soccer and rugby players through a combination of clinical care and longitudinal research. Caleigh Lynch, MSc, a research technician with the Advanced Brain Health Clinic, and Thomas Parker, PhD, a consultant neurologist and clinical lecturer at Imperial College London, are among the researchers involved in the project.
Related to this article
Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.
At a NeurologyLive Clinical Forum in Philadelphia, Jessica D. Schulte, MD, PhD, of NYU Grossman School of Medicine, discussed how earlier recognition and systemic therapy options are changing the treatment paradigm for patients with NF1-associated plexiform neurofibromas.
Benjamin Walter, MD, MBA, discusses how advances in biomarker testing and genetic characterization are informing Parkinson disease care, alongside developments in adaptive deep brain stimulation and efforts to identify disease earlier.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
Advertisement
Advertisement